General Merchandise/HBC

Generex Announces Sales Agreement with Elias Shaker

National brokerage firm to expand distribution of company's consumer product lines
WORCESTER, Mass. -- Generex Biotechnology Corp., a leader in drug delivery for metabolic diseases through the inner lining of the mouth, has entered into a sales agreement with Elias Shaker & Co., a leading national full-service consumer product brokerage firm, to represent Generex's novel consumer products to national and regional retail and wholesale accounts in the United States.

Elias Shaker & Co., Arlington Heights, Ill.,will market and sell the following Generex consumer products: Glucose RapidSpray, Crave-NX Diet Aid Spray, BaBOOM! Energy Spray and Glucose [image-nocss] RapidSpray for Pets.

Elias Shaker has established relationships with all class of trades from national drug chains and wholesalers to mass merchandisers/club stores, grocery chains, food wholesalers, convenience stores and distributors and specialty stores, representing a total of more than 200,000 retail points of purchase throughout the country, it said.

"We are very excited to partner with an experienced and results-driven sales firm such as Elias Shaker to represent our proprietary consumer products in the USA. We welcome the opportunity to have our products showcased and represented by a company with an extensive history in retail," said Rose Perri, the company's COO.

"After reviewing Generex's consumer products, its current distribution and discussing it with our sales team internally we are very confident in taking their product-line to the next level by focusing on building new distribution, supporting established accounts and taking advantage of unique promotional opportunities that may arise which will ultimately grow brand awareness and sales," said Bruce Funk, president of Elias Shaker.

Worcester, Mass.-based Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.It has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the company's proprietary RapidMist device. Its flagship product, buccal insulin (Generex Oral-lyn), which has been approved in India, Lebanon, Algeria and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.

Members help make our journalism possible. Become a CSP member today and unlock exclusive benefits, including unlimited access to all of our content. Sign up here.

Multimedia

Exclusive Content

Foodservice

Opportunities Abound With Limited-Time Offers

For success, complement existing menu offerings, consider product availability and trends, and more, experts say

Snacks & Candy

How Convenience Stores Can Improve Meat Snack, Jerky Sales

Innovation, creative retailers help spark growth in the snack segment

Technology/Services

C-Stores Headed in the Right Direction With Rewards Programs

Convenience operators are working to catch up to the success of loyalty programs in other industries

Trending

More from our partners